Enliven Therapeutics, Inc. (ELVN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Enliven Therapeutics, Inc. (ELVN) Healthcare & Pipeline Overview

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in small molecule kinase inhibitors for cancer, with a focus on ELVN-001 targeting chronic myeloid leukemia and ELVN-002 for HER2-altered cancers, positioning them in the competitive biotechnology landscape.

What Is the Investment Thesis for ELVN?

Enliven Therapeutics presents a notable research candidate within the biotechnology sector, driven by its focused pipeline of small molecule kinase inhibitors targeting specific cancer mutations. The company's lead candidates, ELVN-001 and ELVN-002, are currently in Phase 1 clinical trials, representing significant near-term catalysts as data readouts are anticipated. Positive clinical data could validate the company's approach and drive substantial value appreciation. With a market capitalization of $4.22B, Enliven's valuation reflects the potential of its pipeline, but also carries inherent risks associated with clinical-stage drug development. The company's success hinges on the ability to successfully navigate clinical trials, secure regulatory approvals, and ultimately commercialize its therapies. The low beta of 0.49 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

ELVN Key Highlights

Market capitalization of $4.22B reflects investor confidence in Enliven's pipeline and technology.

• ELVN-001 is currently in Phase 1 clinical trials for chronic myeloid leukemia (CML), targeting a significant unmet need.
• ELVN-002 is in Phase 1 clinical trials for HER2-altered cancers, addressing a genetically defined patient population.
• The company has 62 employees, indicating a focused and efficient operational structure.
• No dividend yield reflects the company's focus on reinvesting earnings into research and development.

Who Are ELVN's Competitors?

ELVN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ELVN's Key Strengths?

Focused pipeline of small molecule kinase inhibitors.

• Targeting specific cancer-driving mutations.
• Strong intellectual property protection.
• Experienced management team.

What Are ELVN's Weaknesses?

Clinical-stage company with no approved products.

• Reliance on successful clinical trial outcomes.
• High cash burn rate.
• Competition from established pharmaceutical companies.

What Could Drive ELVN Stock Higher?

Initial data readout from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia.

• Initial data readout from Phase 1 clinical trial of ELVN-002 in HER2-altered cancers.
• Enrollment and progression of patients in Phase 1 clinical trials for ELVN-001 and ELVN-002.
• Potential for strategic partnerships or collaborations to accelerate drug development.

What Are the Key Risks for ELVN?

Negative return on equity (-18.5%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or setbacks for ELVN-001 and ELVN-002.
• Regulatory delays or rejection of marketing applications.
• Competition from other cancer therapies.
• Dependence on securing additional funding to support research and development.
• Patent challenges or loss of intellectual property protection.

What Are the Growth Opportunities for ELVN?

• Expansion into New Therapeutic Areas: Enliven has the opportunity to leverage its expertise in small molecule kinase inhibitors to expand its pipeline into new therapeutic areas beyond CML and HER2-altered cancers. This could involve targeting other cancer-driving mutations or exploring new mechanisms of action. The market for targeted cancer therapies is expected to continue to grow, providing ample opportunities for Enliven to diversify its portfolio. Timeline: 2-3 years.
• Strategic Partnerships and Collaborations: Enliven can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline. This could involve licensing agreements, co-development deals, or joint ventures. Collaborations can provide access to additional resources, expertise, and market reach. The pharmaceutical industry is increasingly reliant on partnerships to drive innovation. Timeline: Ongoing.
• Advancement of ELVN-001 and ELVN-002 through Clinical Trials: The successful advancement of ELVN-001 and ELVN-002 through clinical trials represents a significant growth opportunity for Enliven. Positive clinical data could lead to regulatory approvals and commercialization, generating substantial revenue. The clinical trial process is lengthy and complex, but successful completion can result in significant value creation. Timeline: Ongoing.
• Geographic Expansion: Enliven can expand its geographic reach beyond the United States by seeking regulatory approvals and commercializing its therapies in other countries. This could involve establishing a presence in key markets such as Europe and Asia. The global market for cancer therapies is substantial, providing ample opportunities for geographic expansion. Timeline: 3-5 years.
• Development of Companion Diagnostics: Enliven can develop companion diagnostics to identify patients who are most likely to benefit from its therapies. This can improve treatment outcomes and reduce healthcare costs. Companion diagnostics are increasingly being used in oncology to personalize treatment decisions. Timeline: 1-2 years.

What Are ELVN's Competitive Advantages?

• Proprietary small molecule inhibitors with novel mechanisms of action.
• Strong intellectual property protection through patents.
• Expertise in kinase inhibitor development.
• Focused pipeline targeting specific cancer mutations.

What Does ELVN Do?

Enliven Therapeutics, Inc., founded with the mission to transform cancer treatment, is a clinical-stage biopharmaceutical company headquartered in Boulder, Colorado. The company is dedicated to discovering and developing innovative small molecule inhibitors that target key drivers of cancer progression. Enliven's approach centers on creating highly selective and potent therapies designed to improve outcomes for patients with various types of cancer. Their pipeline features two primary drug candidates: ELVN-001, a selective BCR-ABL inhibitor currently in Phase 1 clinical trials for adults with chronic myeloid leukemia (CML), and ELVN-002, a HER2 inhibitor undergoing Phase 1 clinical trials for cancers harboring HER2 gene abnormalities. These programs reflect Enliven's commitment to addressing unmet medical needs in oncology by developing targeted therapies that offer improved efficacy and safety profiles compared to existing treatments. Enliven Therapeutics aims to become a leader in precision oncology by advancing its pipeline of novel small molecule inhibitors through clinical development and ultimately delivering transformative therapies to patients in need. The company's focus on specific cancer-driving mutations allows for a more personalized approach to treatment, potentially leading to better outcomes and reduced side effects.

What Products and Services Does ELVN Offer?

• Discovers and develops small molecule inhibitors for cancer treatment.
• Focuses on kinase inhibitors to target specific cancer-driving mutations.
• Develops ELVN-001 for chronic myeloid leukemia (CML).
• Develops ELVN-002 for cancers with HER2 gene abnormalities.
• Conducts Phase 1 clinical trials to evaluate the safety and efficacy of its drug candidates.
• Aims to improve outcomes for patients with various types of cancer.

How Does ELVN Make Money?

• Develops and patents novel small molecule inhibitors.
• Conducts preclinical and clinical research to evaluate the safety and efficacy of its drug candidates.
• Seeks regulatory approvals from the FDA and other regulatory agencies.
• Commercializes its therapies through direct sales or partnerships.

What Industry Does ELVN Operate In?

Enliven Therapeutics operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation, high regulatory hurdles, and significant investment in research and development. The market for cancer therapies is substantial and growing, driven by an aging population and increasing incidence rates. The competitive landscape includes established pharmaceutical companies, as well as numerous emerging biotechs focused on developing novel cancer treatments. Enliven differentiates itself through its focus on small molecule kinase inhibitors targeting specific cancer-driving mutations, positioning it within the precision oncology space. The biotechnology industry is subject to intense regulatory scrutiny, with the FDA playing a critical role in the approval and commercialization of new therapies.

Who Are ELVN's Key Customers?

• Patients with cancer.
• Oncologists and other healthcare professionals.
• Hospitals and cancer centers.
• Pharmaceutical companies (potential partners).

How Enliven Therapeutics, Inc. Is Valued

Enliven Therapeutics, Inc. carries a market capitalization of $4.22B, placing it in the mid-cap category. Analyst price targets span from $65.00 to $82.00, with a consensus of $76.00. At the current price of $59.01, that implies approximately 29% upside potential. Relative to its peer group, ELVN's quantitative score of 80/100 is roughly in line with the peer average of 84/100.

Company Profile

Enliven Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boulder, US. The company is led by CEO Richard A. Fair. ELVN has traded publicly since 2020.

Return on equity for Enliven Therapeutics, Inc. stands at -18.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -11.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 64.07 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.6%, the inverse of the P/E and a quick read on earnings relative to price.

Enliven Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Enliven Therapeutics, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 1.9% above estimates on average.

Wall Street analysts project Enliven Therapeutics, Inc. revenue of about $10K for fiscal 2026, with EPS near $-1.82. The estimate reflects 5 contributing analysts.

ELVN Financials

ELVN Latest News

ELVN Analyst Consensus

ELVN MoonshotScore

Enliven Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources